Lv11
10 积分 2021-08-04 加入
Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast Cancer
2小时前
待确认
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
8天前
已完结
Discovery of Novel Selective Inhibitors of SMARCA2 ATPase Domain by Virtual Screening and Biological Evaluation
10天前
已完结
Discovery of BMS-986365, a first-in-class dual androgen receptor ligand-directed degrader (AR LDD) and antagonist, for the treatment of advanced prostate cancer
1个月前
已完结
First-in-Class Small Molecule to Inhibit CYP11A1 and Steroid Hormone Biosynthesis
1个月前
已完结
Targeting KAT6A/B as a New Therapeutic Strategy for Cancer Therapy
1个月前
已完结
Phase Ib Study of Ribociclib plus Fulvestrant and Ribociclib plus Fulvestrant plus PI3K Inhibitor (Alpelisib or Buparlisib) for HR+ Advanced Breast Cancer
3个月前
已完结
Post-Progression treatment options after CDK4/6 inhibitors in hormone Receptor-Positive HER2-Negative metastatic breast cancer
3个月前
已完结
Options for Endocrine-Refractory, Hormone Receptor–Positive Breast Cancer: Which Target and When?
4个月前
已完结
Management of HER2 alterations in non-small cell lung cancer – The past, present, and future
7个月前
已完结
皖公网安备34019202002308
